We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.

Publications show all

Vermillion has published 1,364 articles.

Patents show all

Vermillion has 1 licensable patents.
341Applications180Issued

Clinical Trials show all

2N/A

SEC Filings show all

8-K21810-Q5110-K15D3S-11

SEC Form D Funding Events

DateOfferedSoldType
2013-05-24$13,242,500$13,242,500Equity, Option to Acquire
2010-01-12$43,049,858$43,049,858Equity
2007-09-17UnknownUnknownOther (Paper Filing)

Key Executives

  • Gail S. Page
    Director
  • John F. Hamilton
    Director
  • James S. Burns
    Director
  • Thomas McLain
    Executive Officer
  • Eric Schoen
    Executive Officer
  • Donald Munroe
    Executive Officer
  • William Creech
    Executive Officer
  • Bruce Huebner
    Director
  • James Burns
    Director
  • Peter Roddy
    Director
  • Carl Severinghaus
    Director
  • William Wallen
    Director
  • Robert Goggin
    Director